Literature DB >> 17624732

Erk5 is activated and acts as a survival factor in mitosis.

Ana Gírio1, Juan Carlos Montero, Atanasio Pandiella, Sukalyan Chatterjee.   

Abstract

Erk5 is a recently discovered MAPK claimed to be responsible for some of the roles attributed to Erk1/2; here we report that it is activated in mitosis in comparison to G1/S. When Erk5 is inactivated pharmacologically or largely ablated by RNAi, cell survival in mitosis is diminished. We have previously shown Bim, a BH3-only protein of the Bcl-2 family, to be phosphorylated in mitosis, in a MEK-dependent manner (M. Grãos, A. D. Almeida, S. Chatterjee, Biochem. J. 388 (2005) 185). Inactivation of Erk5 in mitosis causes dephosphorylation of Bim. Bim is in the mitochondria in mitosis and when dephosphorylated interacts with Bax, inducing caspase activation. We also show that in mitosis Bim co-immunoprecipitates with Erk5 and Erk5 phosphorylates GST-Bim in in vitro kinase reaction. Taken together, our results identify a new target of the still largely mysterious Erk5 and suggest that Erk5 in mitosis may be a decisive step for the survival of proliferating cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17624732     DOI: 10.1016/j.cellsig.2007.05.005

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  12 in total

1.  Neuregulin1β Effects on Brain Tissue via ERK5-Dependent MAPK Pathway in a Rat Model of Cerebral Ischemia-Reperfusion Injury.

Authors:  Ning Gu; Keli Ge; Cui Hao; Yaqing Ji; Hongyun Li; Yunliang Guo
Journal:  J Mol Neurosci       Date:  2017-03-06       Impact factor: 3.444

2.  Bim vanishes in the light of a mitotic Aurora.

Authors:  L L Fava; M D Haschka; A Villunger
Journal:  Cell Death Differ       Date:  2013-12       Impact factor: 15.828

3.  BAY-885, a mitogen-activated protein kinase kinase 5 inhibitor, induces apoptosis by regulating the endoplasmic reticulum stress/Mcl-1/Bim pathway in breast cancer cells.

Authors:  Lei Wang; Xiaochun Ji; Chenxiao Mao; Rui Yu
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

4.  The activity of extracellular signal-regulated kinase is required during G2/M phase before metaphase-anaphase transition in synchronized leukemia cell lines.

Authors:  Katarina Matkovic; Vesna Lukinovic-Skudar; Hrvoje Banfic; Dora Visnjic
Journal:  Int J Hematol       Date:  2009-01-17       Impact factor: 2.490

5.  Calcium regulation of EGF-induced ERK5 activation: role of Lad1-MEKK2 interaction.

Authors:  Zhong Yao; Seunghee Yoon; Eyal Kalie; Ziv Raviv; Rony Seger
Journal:  PLoS One       Date:  2010-09-07       Impact factor: 3.240

6.  BimEL is phosphorylated at mitosis by Aurora A and targeted for degradation by βTrCP1.

Authors:  M Moustafa-Kamal; I Gamache; Y Lu; S Li; J G Teodoro
Journal:  Cell Death Differ       Date:  2013-08-02       Impact factor: 15.828

7.  miR-143 overexpression impairs growth of human colon carcinoma xenografts in mice with induction of apoptosis and inhibition of proliferation.

Authors:  Pedro M Borralho; André E S Simões; Sofia E Gomes; Raquel T Lima; Tânia Carvalho; Duarte M S Ferreira; Maria H Vasconcelos; Rui E Castro; Cecília M P Rodrigues
Journal:  PLoS One       Date:  2011-08-25       Impact factor: 3.240

8.  Overexpression of MEKK2 is associated with colorectal carcinogenesis.

Authors:  Li Jiang; Meijin Huang; Lei Wang; Xinjuan Fan; Puning Wang; Daohai Wang; Xinhui Fu; Jianping Wang
Journal:  Oncol Lett       Date:  2013-08-29       Impact factor: 2.967

9.  Aberrant MEK5/ERK5 signalling contributes to human colon cancer progression via NF-κB activation.

Authors:  A E S Simões; D M Pereira; S E Gomes; H Brito; T Carvalho; A French; R E Castro; C J Steer; S N Thibodeau; C M P Rodrigues; P M Borralho
Journal:  Cell Death Dis       Date:  2015-04-09       Impact factor: 8.469

10.  Hypoxia-induced modulation of apoptosis and BCL-2 family proteins in different cancer cell types.

Authors:  Audrey Sermeus; Marie Genin; Amélie Maincent; Maude Fransolet; Annick Notte; Lionel Leclere; Hélène Riquier; Thierry Arnould; Carine Michiels
Journal:  PLoS One       Date:  2012-11-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.